[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE270285T1 - 4-substituiertes furan-2-sulfonamid und dessen verwendung in der herstellung von sulfonylharnstoff-derivate - Google Patents

4-substituiertes furan-2-sulfonamid und dessen verwendung in der herstellung von sulfonylharnstoff-derivate

Info

Publication number
ATE270285T1
ATE270285T1 AT02020749T AT02020749T ATE270285T1 AT E270285 T1 ATE270285 T1 AT E270285T1 AT 02020749 T AT02020749 T AT 02020749T AT 02020749 T AT02020749 T AT 02020749T AT E270285 T1 ATE270285 T1 AT E270285T1
Authority
AT
Austria
Prior art keywords
sulfonamide
production
urea derivatives
sulfonyl urea
substituted furan
Prior art date
Application number
AT02020749T
Other languages
English (en)
Inventor
Mark Anthony Dombroski
James Frederick Eggler
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE270285T1 publication Critical patent/ATE270285T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/60—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT02020749T 1997-01-29 1997-12-29 4-substituiertes furan-2-sulfonamid und dessen verwendung in der herstellung von sulfonylharnstoff-derivate ATE270285T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3697997P 1997-01-29 1997-01-29

Publications (1)

Publication Number Publication Date
ATE270285T1 true ATE270285T1 (de) 2004-07-15

Family

ID=21891776

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02020749T ATE270285T1 (de) 1997-01-29 1997-12-29 4-substituiertes furan-2-sulfonamid und dessen verwendung in der herstellung von sulfonylharnstoff-derivate
AT97947201T ATE242208T1 (de) 1997-01-29 1997-12-29 Sulfonylharnstoff-derivate und ihre verwendung in der kontrolle der interleukin-1-aktivität

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT97947201T ATE242208T1 (de) 1997-01-29 1997-12-29 Sulfonylharnstoff-derivate und ihre verwendung in der kontrolle der interleukin-1-aktivität

Country Status (40)

Country Link
US (2) US6166064A (de)
EP (1) EP0964849B1 (de)
JP (1) JP3573757B2 (de)
KR (1) KR100324058B1 (de)
CN (1) CN1127479C (de)
AP (1) AP929A (de)
AR (1) AR011093A1 (de)
AT (2) ATE270285T1 (de)
AU (1) AU723895B2 (de)
BG (1) BG103597A (de)
BR (1) BR9714328A (de)
CA (1) CA2279186C (de)
CO (1) CO4920230A1 (de)
CZ (1) CZ293173B6 (de)
DE (2) DE69722663T2 (de)
DK (2) DK1270565T3 (de)
DZ (1) DZ2407A1 (de)
EA (1) EA001803B1 (de)
ES (2) ES2198598T3 (de)
HR (1) HRP980045B1 (de)
HU (1) HUP0000567A3 (de)
ID (1) ID22223A (de)
IL (1) IL130855A0 (de)
IS (1) IS5099A (de)
MA (1) MA26468A1 (de)
NO (1) NO313279B1 (de)
NZ (1) NZ336248A (de)
OA (1) OA11079A (de)
PA (1) PA8444701A1 (de)
PE (1) PE57898A1 (de)
PL (1) PL335052A1 (de)
PT (2) PT964849E (de)
SK (1) SK283679B6 (de)
TN (1) TNSN98017A1 (de)
TR (1) TR199901816T2 (de)
TW (1) TW515788B (de)
UY (1) UY24861A1 (de)
WO (1) WO1998032733A1 (de)
YU (1) YU33799A (de)
ZA (1) ZA98685B (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022984A (en) * 1998-07-27 2000-02-08 Pfizer Inc. Efficient synthesis of furan sulfonamide compounds useful in the synthesis of new IL-1 inhibitors
EP1526383A3 (de) * 1998-08-31 2005-11-16 Pfizer Products Inc. Diarylsulphonylharnstoff-Bindungsproteine
IT1303249B1 (it) * 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
AU6464400A (en) * 1999-09-14 2001-04-17 Pfizer Products Inc. Combination treatment with il-1ra and diaryl sulphonyl urea compounds
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
CA2369967A1 (en) * 2001-02-12 2002-08-12 Joseph Anthony Cornicelli Methods of treating nuclear factor-kappa b mediated diseases and disorders
CN1547486A (zh) 2001-06-26 2004-11-17 抗opgl抗体
CA2459454A1 (en) 2001-09-14 2003-03-27 Bayer Pharmaceuticals Corporation Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists
MXPA04002565A (es) * 2001-11-30 2004-05-31 Pfizer Prod Inc Combinacion de un inhibidor de il-1/18 con un inhibidor de tnf para el tratamiento de inflamacion.
US20030131370A1 (en) * 2001-12-14 2003-07-10 Pfizer Inc. Disruption of the glutathione S-transferase-Omega-1 gene
AU2003245989A1 (en) 2002-07-09 2004-01-23 Boehringer Ingelheim Pharma Gmbh And Co. Kg Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
AR041173A1 (es) 2002-09-06 2005-05-04 Amgen Inc Aniticuerpo monoclonal anti- il- 1r1 humano terapeutico
AU2003263560A1 (en) * 2002-10-03 2004-04-23 Pfizer Products Inc. Use of gst-omega-2 as a therapeutic target
CL2004002015A1 (es) 2003-08-06 2005-05-13 Senomyx Inc Derivados de amida, productos que las contienen, utiles para modificar el sabor de alimentos y medicamentos.
ATE444286T1 (de) * 2004-03-23 2009-10-15 Dompe Pha R Ma Spa Res & Mfg 2-phenylpropionsäurederivate und diese enthaltende pharmazeutische zusammensetzung
US20060045953A1 (en) * 2004-08-06 2006-03-02 Catherine Tachdjian Aromatic amides and ureas and their uses as sweet and/or umami flavor modifiers, tastants and taste enhancers
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
WO2006084186A2 (en) 2005-02-04 2006-08-10 Senomyx, Inc. Compounds comprising linked hetero aryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions
WO2006090932A1 (ja) * 2005-02-28 2006-08-31 Eisai R & D Managemant Co., Ltd. スルホンアミド化合物の代理マーカー
US7208526B2 (en) * 2005-05-20 2007-04-24 Hoffmann-La Roche Inc. Styrylsulfonamides
TW200715993A (en) 2005-06-15 2007-05-01 Senomyx Inc Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers
KR101387563B1 (ko) 2006-04-21 2014-04-25 세노믹스, 인코포레이티드 고효능의 조미용 향료를 포함하는 식품 조성물 및 이의 제조 방법
EP1992344A1 (de) 2007-05-18 2008-11-19 Institut Curie P38 Alpha als therapeutisches Target für Erkrankungen, die mit einer FGFR3- Mutation assoziiert sind
US7973051B2 (en) * 2007-11-30 2011-07-05 Hoffman-La Roche Inc. Aminothiazoles as FBPase inhibitors for diabetes
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
US10385040B2 (en) 2014-08-12 2019-08-20 Loyola University Of Chicago Indoline sulfonamide inhibitors of DapE and NDM-1 and use of the same
AU2016222278B2 (en) 2015-02-16 2020-07-09 The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Sulfonylureas and related compounds and use of same
WO2016138473A1 (en) * 2015-02-26 2016-09-01 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inflammasome activation in myelodysplastic syndromes
FR3046933B1 (fr) 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
EP3416948B1 (de) * 2016-02-16 2024-07-24 The University Of Queensland Indazen aufweisende sulfonylharnstoffe als entzündungshemmstoffe
EP3445757B1 (de) * 2016-04-18 2020-11-25 Novartis Inflammasome Research, Inc. Verbindungen und zusammensetzungen zur behandlung von leiden in zusammenhang mit der nlrp-aktivität
EP3445749B1 (de) * 2016-04-18 2022-12-21 Novartis AG Verbindungen und zusammensetzungen zur behandlung von erkrankungen in zusammenhang mit nlrp-aktivität
EP3272739A1 (de) * 2016-07-20 2018-01-24 NodThera Limited Sulfonylharnstoff-derivate und ihre verwendung in der kontrole der interleukin-1-aktivität
AU2017367086A1 (en) * 2016-11-29 2019-07-18 Epizyme, Inc. Compounds containing a sulfonic group as KAT inhibitors
CN110366549A (zh) 2017-01-23 2019-10-22 基因泰克公司 作为白介素-1活性抑制剂的化合物
US11840543B2 (en) 2017-05-24 2023-12-12 The University Of Queensland Compounds and uses
EP3634951B8 (de) 2017-06-09 2024-08-21 Zydus Lifesciences Limited Neuartige substituierte sulfoximinverbindungen
EP3649112A1 (de) 2017-07-07 2020-05-13 Inflazome Limited Sulfonylharnstoffe und sulfonylthioharnstoffe als nlrp3-inhibitoren
IL271716B2 (en) 2017-07-07 2024-09-01 Inflazome Ltd Sulfonamide Carboxamide Compounds as NLRP3 Inhibitors, Pharmaceutical Preparations and Their Uses
PT3658539T (pt) 2017-07-24 2024-04-26 Novartis Ag Compostos e composições para tratar condições associadas à atividade de nlrp
EP3668843A1 (de) 2017-08-15 2020-06-24 Inflazome Limited Sulfonylharnstoffe und sulfonylthioharnstoffe als nlrp3-inhibitoren
US11613542B2 (en) 2017-08-15 2023-03-28 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
US11518739B2 (en) 2017-08-15 2022-12-06 Inflazome Limited Sulfonamide carboxamide compounds
BR112020002906A2 (pt) 2017-08-15 2020-08-04 Inflazome Limited novos compostos de sulfonamida-carboxamida
EP3668842A1 (de) 2017-08-15 2020-06-24 Inflazome Limited Sulfonylharnstoffe und sulfonylthioharnstoffe als nlrp3-inhibitoren
WO2019043610A1 (en) 2017-08-31 2019-03-07 Cadila Healthcare Limited NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
WO2019068772A1 (en) 2017-10-03 2019-04-11 Inflazome Limited NEW COMPOUNDS
WO2019079119A1 (en) 2017-10-17 2019-04-25 IFM Tre, Inc. SULFONAMIDES AND ASSOCIATED COMPOSITIONS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH NLRP ACTIVITY
MX2020004423A (es) 2017-11-09 2020-08-06 Inflazome Ltd Nuevos compuestos de sulfonamida carboxamida.
GB201721185D0 (en) * 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
CN108299256B (zh) * 2018-01-09 2019-09-10 武汉大学 一类2,3,4-三羟基苯磺酰胺衍生物及其制备方法和应用
EP3759090A1 (de) 2018-03-02 2021-01-06 Inflazome Limited Neuartige verbindungen
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
WO2019166632A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
US11884645B2 (en) 2018-03-02 2024-01-30 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
EP3759102A1 (de) 2018-03-02 2021-01-06 Inflazome Limited Neuartige verbindungen
JP2021529187A (ja) * 2018-07-03 2021-10-28 ノバルティス アーゲー Ｎｌｒｐモジュレータ
CR20210024A (es) * 2018-07-20 2021-02-22 Hoffmann La Roche Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
CN113056451A (zh) 2018-10-24 2021-06-29 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
SG11202107680PA (en) 2019-01-14 2021-08-30 Cadila Healthcare Ltd Novel substituted sulfonylurea derivatives
FI3983387T3 (fi) 2019-06-12 2024-07-09 Nodthera Ltd Sulfonyyliureajohdannaisia ja niiden käyttötarkoituksia
WO2020254697A1 (en) 2019-06-21 2020-12-24 Ac Immune Sa Fused 1,2 thiazoles and 1,2 thiazines which act as nl3p3 modulators
US20220313657A1 (en) * 2019-09-12 2022-10-06 Cadila Healthcare Limited Novel substituted sulfoximine derivatives
EP4166541A4 (de) * 2020-06-11 2024-09-04 Cisen Pharmaceutical Co Ltd Dimethylsulfoximin-derivat
CA3178361A1 (en) 2020-06-19 2021-12-23 Emanuele Gabellieri Dihydrooxazole and thiourea derivatives modulating the nlrp3 inflammasome pathway
WO2022022646A1 (zh) * 2020-07-29 2022-02-03 南京明德新药研发有限公司 含硒五元杂芳环化合物
JP2023540733A (ja) 2020-09-04 2023-09-26 ノッドセラ リミテッド アルキルオキサシクロアルキル部分を含むスルファモイル尿素誘導体およびその使用
ES2948511A1 (es) * 2021-09-08 2023-09-13 Fundacion Para La Investigacion Biomedica Del Hospital Univ De La Princesa Derivados de n-sulfonilureas y su uso terapeutico
WO2023098612A1 (zh) * 2021-12-03 2023-06-08 南京明德新药研发有限公司 二甲基亚磺酰亚胺衍生物的盐型及晶型
EP4452972A1 (de) 2021-12-22 2024-10-30 AC Immune SA Dihydro-oxazolderivatverbindungen
AR128498A1 (es) * 2022-02-15 2024-05-15 Hoffmann La Roche Procesos novedosos
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation
US20240034735A1 (en) 2022-07-14 2024-02-01 Ac Immune Sa Novel compounds
WO2024023266A1 (en) 2022-07-28 2024-02-01 Ac Immune Sa Novel compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4586950A (en) * 1982-05-31 1986-05-06 E. I. Du Pont De Nemours & Company Novel phenyl-substituted sulfonamides
US4780125A (en) * 1982-09-01 1988-10-25 Ciba-Geigy Corporation N-phenylsulfonyl-N'-triazinylureas
DE3927369A1 (de) * 1989-08-19 1991-02-21 Bayer Ag Substituierte n-(chinolin-2-yl-methoxy)benzyl-sulfonyl-harnstoffe
US5064851A (en) * 1990-07-24 1991-11-12 Pfizer Inc. 3-(1-substituted-pyrazoyl)-2-oxindole derivatives, compositions and use
US5254589A (en) * 1991-10-15 1993-10-19 Warner-Lambert Company Sulfonyl urea and carbamate ACAT inhibitors
DE4344957A1 (de) * 1993-12-30 1995-07-06 Hoechst Ag Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Herstellungsverfahren und Verwendungsmöglichkeiten pharmazeutischer Präparate auf Basis dieser Verbindungen
CN1038679C (zh) * 1994-12-07 1998-06-10 南开大学 磺酰脲类化合物及其除草用途
HU226462B1 (en) * 1995-02-17 2008-12-29 Hoechst Ag Substituted benzol-sulfonyl-ureas and -thioureas, process for producing them, pharmaceutical compositions containing them, and their use
AU6967198A (en) * 1997-04-10 1998-10-30 Eli Lilly And Company Diarylsulfonylureas for use in treating secretory diarrhea

Also Published As

Publication number Publication date
NO993658L (no) 1999-09-28
ATE242208T1 (de) 2003-06-15
HUP0000567A2 (hu) 2000-10-28
DE69722663T2 (de) 2004-04-29
PT1270565E (pt) 2004-09-30
HRP980045B1 (en) 2002-10-31
OA11079A (en) 2002-03-14
ES2222426T3 (es) 2005-02-01
JP2000511200A (ja) 2000-08-29
NZ336248A (en) 2000-10-27
SK283679B6 (sk) 2003-11-04
IL130855A0 (en) 2001-01-28
ZA98685B (en) 1999-07-29
KR100324058B1 (ko) 2002-02-16
EP0964849A1 (de) 1999-12-22
DK0964849T3 (da) 2003-08-25
UY24861A1 (es) 2000-09-29
SK98299A3 (en) 2001-10-08
AR011093A1 (es) 2000-08-02
PL335052A1 (en) 2000-03-27
ES2198598T3 (es) 2004-02-01
DE69729762D1 (de) 2004-08-05
CZ293173B6 (cs) 2004-02-18
TW515788B (en) 2003-01-01
CO4920230A1 (es) 2000-05-29
WO1998032733A1 (en) 1998-07-30
HUP0000567A3 (en) 2002-10-28
CN1127479C (zh) 2003-11-12
US6166064A (en) 2000-12-26
DE69729762T2 (de) 2005-07-14
PA8444701A1 (es) 2000-05-24
BR9714328A (pt) 2000-03-21
CA2279186A1 (en) 1998-07-30
EA001803B1 (ru) 2001-08-27
JP3573757B2 (ja) 2004-10-06
AP9801190A0 (en) 1998-03-31
TR199901816T2 (xx) 1999-11-22
MA26468A1 (fr) 2004-12-20
DE69722663D1 (de) 2003-07-10
EA199900603A1 (ru) 2000-02-28
CN1245490A (zh) 2000-02-23
CA2279186C (en) 2004-02-24
AU5234098A (en) 1998-08-18
EP0964849B1 (de) 2003-06-04
US6433009B1 (en) 2002-08-13
AP929A (en) 2001-01-18
DK1270565T3 (da) 2004-10-04
NO313279B1 (no) 2002-09-09
AU723895B2 (en) 2000-09-07
CZ257599A3 (cs) 2000-09-13
DZ2407A1 (fr) 2003-01-04
ID22223A (id) 1999-09-16
IS5099A (is) 1999-06-29
HRP980045A2 (en) 1999-06-30
NO993658D0 (no) 1999-07-28
TNSN98017A1 (fr) 2005-03-15
BG103597A (bg) 2000-02-29
KR20000070541A (ko) 2000-11-25
PT964849E (pt) 2003-08-29
PE57898A1 (es) 1999-06-11
YU33799A (sh) 2002-03-18

Similar Documents

Publication Publication Date Title
ATE270285T1 (de) 4-substituiertes furan-2-sulfonamid und dessen verwendung in der herstellung von sulfonylharnstoff-derivate
DE59800980D1 (de) Mischungen von Reaktivfarbstoffen und deren Verwendung
DE69935473D1 (de) Katalysator und dessen Verwendung in der Herstellung von Vinylacetat
DE69805515D1 (de) Aminophenolderivate und ihre verwendung in der kosmetik
DE69908499D1 (de) Polymerisierbare bis-sulfonylderivate und ihre verwendung in der herstellung von ionenaustauschermembranen
DE69518645D1 (de) Herstellung von 1,2-dihydro und 2,2-dihydro hexafluorpropanen und ihre azeotrope mit hf
DE59814449D1 (de) Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE69627411D1 (de) Triazinderivate, ihre Herstellung und Verwendung
DE69814431D1 (de) 3,3-diarylpropylamine , ihre verwendung und herstellung
DE69623992D1 (de) Derivate von dolestatin, deren herstellung und verwendung
DE69821623D1 (de) Derivate von acyl-piperazinil-pyrimidinen, ihre herstellung und verwendung als medikament
DE60002526D1 (de) Herstellung von Tricyclodecandicarbaldehyd, Pentacyclopentadecandicarbaldehyd und der entsprechenden Dimethanole
DE59404704D1 (de) Faserreaktive Farbstoffe, ihre Herstellung und Verwendung
DE59403353D1 (de) Faserreaktive Farbstoffe, ihre Herstellung und Verwendung
DE59703980D1 (de) Reaktivfarbstoffe, ihre Herstellung und Verwendung
ATA3589A (de) Neue isochinolinderivate, ihre herstellung und ihre verwendung
DE59702018D1 (de) Azofarbstoffe, ihre Herstellung und Verwendung
DE59409541D1 (de) Bicyclen-derivate, ihre herstellung und verwendung
DE69916195D1 (de) Polythioether und ihre Verwendung
DE69521595D1 (de) Optisch-aktives Benzothiepin-Derivate, ihre Herstellung und Verwendung
DE69808266D1 (de) Herstellung und verwendung von alpha-ketoamid derivate und anordnunge
DE59710272D1 (de) Neue alpha-hydroxysäurederivate, ihre herstellung und verwendung
DE69510223D1 (de) Herstellung von 2-chlor-2-hydrohexafluorpropan und ihre azeotropen mit hf
DE69806419D1 (de) Harzzusammensetzung und ihre Verwendung
DE69517345D1 (de) Abziehbarer Verbundstoff und seiner Verwendung bei der Herstellung von Ausgleichsscheiben

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1270565

Country of ref document: EP

REN Ceased due to non-payment of the annual fee